128 related articles for article (PubMed ID: 37918494)
1. Genipin-crosslinked albumin nanoparticles containing neratinib and silibinin: A dual-death therapy for triple negative breast cancer.
Ghadi R; Pandey PK; Gabhale A; Wadikar A; Dharshini M; Kuche K; Date T; Jain S
Int J Pharm; 2023 Dec; 648():123570. PubMed ID: 37918494
[TBL] [Abstract][Full Text] [Related]
2. Yttrium Oxide nanoparticles induce cytotoxicity, genotoxicity, apoptosis, and ferroptosis in the human triple-negative breast cancer MDA-MB-231 cells.
Emad B; WalyEldeen AA; Hassan H; Sharaky M; Abdelhamid IA; Ibrahim SA; Mohamed HR
BMC Cancer; 2023 Nov; 23(1):1151. PubMed ID: 38012585
[TBL] [Abstract][Full Text] [Related]
3. Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumour-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer.
Vysyaraju NR; Paul M; Ch S; Ghosh B; Biswas S
J Drug Target; 2022 Dec; 30(10):1088-1105. PubMed ID: 35723068
[TBL] [Abstract][Full Text] [Related]
4. Nano-inducer of ferroptosis for targeted chemotherapy of human triple negative breast carcinoma.
Shetake NG; Das SK; Kumar A; Pandey BN
Biomater Adv; 2024 Jul; 161():213868. PubMed ID: 38677038
[TBL] [Abstract][Full Text] [Related]
5. Unlocking apoptosis in triple negative breast cancer: Harnessing "glutamine trap" to amplify the efficacy of lapatinib-loaded mixed micelles.
Ghadi R; Kuche K; Date T; Nallamothu B; Chaudhari D; Jain S
Biomater Adv; 2024 May; 159():213822. PubMed ID: 38442461
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting the proliferation, migration and invasion of triple negative breast cancer cells through anti-tumor human serum albumin nanoparticles loading aziditaxel as a novel taxane derivative.
Chen LQ; Zhang ZM; Huang W; Gao ZG; Fang WS; Jin MJ; Yu L
Pharmazie; 2017 Mar; 72(3):152-160. PubMed ID: 29442050
[TBL] [Abstract][Full Text] [Related]
7. Self-Assembled Dual-Targeted Epirubicin-Hybrid Polydopamine Nanoparticles for Combined Chemo-Photothermal Therapy of Triple-Negative Breast Cancer.
Li X; Zou Q; Zhang J; Zhang P; Zhou X; Yalamarty SSK; Liang X; Liu Y; Zheng Q; Gao J
Int J Nanomedicine; 2020; 15():6791-6811. PubMed ID: 32982234
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of micellar-like terpolymer nanoparticles with reductively-cleavable cross-links and evaluation of efficacy in 2D and 3D models of triple negative breast cancer.
Monteiro PF; Gulfam M; Monteiro CJ; Travanut A; Abelha TF; Pearce AK; Jerôme C; Grabowska AM; Clarke PA; Collins HM; Heery DM; Gershkovich P; Alexander C
J Control Release; 2020 Jul; 323():549-564. PubMed ID: 32371266
[TBL] [Abstract][Full Text] [Related]
9. Exploring paclitaxel-loaded adenosine-conjugated PEGylated PLGA nanoparticles for targeting triple-negative breast cancer.
Chaudhari D; Kuche K; Yadav V; Ghadi R; Date T; Bhargavi N; Jain S
Drug Deliv Transl Res; 2023 Apr; 13(4):1074-1087. PubMed ID: 36528709
[TBL] [Abstract][Full Text] [Related]
10. Silibinin inhibits migration and invasion of breast cancer MDA-MB-231 cells through induction of mitochondrial fusion.
Si L; Fu J; Liu W; Hayashi T; Nie Y; Mizuno K; Hattori S; Fujisaki H; Onodera S; Ikejima T
Mol Cell Biochem; 2020 Jan; 463(1-2):189-201. PubMed ID: 31612353
[TBL] [Abstract][Full Text] [Related]
11. Combination Organelle Mitochondrial Endoplasmic Reticulum Therapy (COMET) for Multidrug Resistant Breast Cancer.
Milane LS; Dolare S; Ren G; Amiji M
J Control Release; 2023 Nov; 363():435-451. PubMed ID: 37717658
[TBL] [Abstract][Full Text] [Related]
12. Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer.
Lee SY; Cho HJ
Biomacromolecules; 2019 Feb; 20(2):835-845. PubMed ID: 30566834
[TBL] [Abstract][Full Text] [Related]
13. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
14. Transferrin Coated d-penicillamine-Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers.
Shome R; Ghosh SS
ACS Appl Bio Mater; 2021 Jun; 4(6):5033-5048. PubMed ID: 35007052
[TBL] [Abstract][Full Text] [Related]
15. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
16. Ferroptosis-enhanced chemotherapy for triple-negative breast cancer with magnetic composite nanoparticles.
Zhang J; Zhou K; Lin J; Yao X; Ju D; Zeng X; Pang Z; Yang W
Biomaterials; 2023 Dec; 303():122395. PubMed ID: 37988899
[TBL] [Abstract][Full Text] [Related]
17. A Novel Derivative of Curcumol, HCL-23, Inhibits the Malignant Phenotype of Triple-Negative Breast Cancer and Induces Apoptosis and HO-1-Dependent Ferroptosis.
Zhao P; Song H; Gao F; Chen L; Qiu J; Jin J; Pan C; Tang Y; Chen M; Pan Y; Li Y; Huang L; Yang J; Hao X
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110625
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management.
Kushwah V; Katiyar SS; Dora CP; Kumar Agrawal A; Lamprou DA; Gupta RC; Jain S
Acta Biomater; 2018 Jun; 73():424-436. PubMed ID: 29649635
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Potential of Albumin Nanoparticles Encapsulated Visnagin in MDA-MB-468 Triple-Negative Breast Cancer Cells.
Alsrhani A; Elderdery AY; Alzahrani B; Alzerwi NAN; Althobiti MM; Rayzah M; Idrees B; Elkhalifa AME; Subbiah SK; Mok PL
Molecules; 2023 Apr; 28(7):. PubMed ID: 37049991
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Intervention Nanoparticles for Triple-Negative Breast Cancer Therapy via Overcoming FSP1-Mediated Ferroptosis Resistance.
Yang J; Jia Z; Zhang J; Pan X; Wei Y; Ma S; Yang N; Liu Z; Shen Q
Adv Healthc Mater; 2022 Jul; 11(13):e2102799. PubMed ID: 35395704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
